Review



foxp3 fixation permeabilization buffer  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Miltenyi Biotec foxp3 fixation permeabilization buffer
    Foxp3 Fixation Permeabilization Buffer, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 230 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/FoxP3+Staining+Buffer+Set/bio_rxiv__2025__07__17__665275-209-6-9
    Average 97 stars, based on 230 article reviews
    foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Glucose metabolism controls monocyte homeostasis and migration but has no impact on atherosclerosis development in mice
    Article Snippet: Cells were first stained with Live/Dead fixable viability dye, washed, and incubated with Fc Block (2.4G2, BioXcell) before surface staining. .. Cells were fixed and permeabilized using Foxp3 fixation/permeabilization buffer (Miltenyi) and then stained with anti-Puromycin (Alexa Fluor 647). ..

    Article Title: CSF1R regulates monocyte subset differentiation and intracellular metabolism
    Article Snippet: Cells were first stained with Live/Dead fixable viability dye, washed, and incubated with Fc Block (2.4G2, BioXcell) before surface staining. .. Cells were fixed and permeabilized using Foxp3 fixation/permeabilization buffer (Miltenyi) and then stained with anti-Puromycin (Alexa Fluor 647). ..

    Article Title: Unravelling the sex-specific diversity and functions of adrenal gland macrophages
    Article Snippet: Cells were first stained with Live/Dead fixable viability dye, washed, and incubated with Fc Block (2.4G2, BioXcell) before surface staining. .. Cells were fixed and permeabilized using Foxp3 fixation/permeabilization buffer (Miltenyi) and then stained with anti-Puromycin (Alexa Fluor 647). ..



    Similar Products

    foxp3 fixation permeabilization buffer  (Miltenyi Biotec)
    97
    Miltenyi Biotec foxp3 fixation permeabilization buffer
    Foxp3 Fixation Permeabilization Buffer, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/FoxP3+Staining+Buffer+Set/bio_rxiv__2025__07__17__665275-209-6-9
    Average 97 stars, based on 1 article reviews
    foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    foxp3 transcription factor fixation permeabilization buffer  (Cytek Biosciences)
    97
    Cytek Biosciences foxp3 transcription factor fixation permeabilization buffer
    Foxp3 Transcription Factor Fixation Permeabilization Buffer, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/Foxp3+%2F+Transcription+Factor+Staining+Buffer+Kit/pm41467787-420-19-23
    Average 97 stars, based on 1 article reviews
    foxp3 transcription factor fixation permeabilization buffer - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    foxp3 fixation permeabilization buffer  (Thermo Fisher)
    99
    Thermo Fisher foxp3 fixation permeabilization buffer
    a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
    Foxp3 Fixation Permeabilization Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/Sucrose/bio_rxiv__2025__10__27__684825-348-14-17
    Average 99 stars, based on 1 article reviews
    foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    fixation permeabilization solution  (Cytek Biosciences)
    97
    Cytek Biosciences fixation permeabilization solution
    a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
    Fixation Permeabilization Solution, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/Foxp3+%2F+Transcription+Factor+Staining+Buffer+Kit/bio_rxiv__2025__10__25__684515-300-11-13
    Average 97 stars, based on 1 article reviews
    fixation permeabilization solution - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    ebiosciencetm foxp3 fixation permeabilization buffer  (Novus Biologicals)
    95
    Novus Biologicals ebiosciencetm foxp3 fixation permeabilization buffer
    a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
    Ebiosciencetm Foxp3 Fixation Permeabilization Buffer, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/FoxP3/pmc12701028-65-7-27
    Average 95 stars, based on 1 article reviews
    ebiosciencetm foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    foxp3/transcription factor fixation and permeabilization buffer  (Thermo Fisher)
    90
    Thermo Fisher foxp3/transcription factor fixation and permeabilization buffer
    a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
    Foxp3/Transcription Factor Fixation And Permeabilization Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/intracellular+fixation+++permeabilization+buffer+set/pmc12254219-447-10-12
    Average 90 stars, based on 1 article reviews
    foxp3/transcription factor fixation and permeabilization buffer - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    foxp3 fixation/permeabilization buffer set  (Thermo Fisher)
    90
    Thermo Fisher foxp3 fixation/permeabilization buffer set
    a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
    Foxp3 Fixation/Permeabilization Buffer Set, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxp3+fixation+permeabilization+buffer/foxp3+transcription+factor+staining+buffer+set/pmc12213756-88-9-13
    Average 90 stars, based on 1 article reviews
    foxp3 fixation/permeabilization buffer set - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + Foxp3 + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.

    Journal: bioRxiv

    Article Title: Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumour cells

    doi: 10.1101/2025.10.27.684825

    Figure Lengend Snippet: a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + Foxp3 + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.

    Article Snippet: Subsequently, extracellular master mix, prepared with the antibodies listed in Table S6 diluted in Foxp3 Fixation/Permeabilization Buffer (Invitrogen, 00-5523-00), was added and samples were incubated for 30 min at 4°C.

    Techniques: Flow Cytometry, Mutagenesis